K
Kai Wu
Publications - 15
Citations - 2652
Kai Wu is an academic researcher. The author has contributed to research in topics: Neutralizing antibody & Neutralization. The author has an hindex of 9, co-authored 15 publications receiving 1137 citations.
Papers
More filters
Journal ArticleDOI
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.
Kizzmekia S. Corbett,Darin K. Edwards,Sarah R. Leist,Olubukola M. Abiona,Seyhan Boyoglu-Barnum,Rebecca A. Gillespie,Sunny Himansu,Alexandra Schäfer,Cynthia T. Ziwawo,Anthony T. DiPiazza,Kenneth H. Dinnon,Sayda Elbashir,Christine A. Shaw,Angela Woods,Ethan J. Fritch,David R. Martinez,Kevin W. Bock,Mahnaz Minai,Bianca M. Nagata,Geoffrey B. Hutchinson,Kai Wu,Carole Henry,Kapil Bahl,Dario Garcia-Dominguez,Ling Zhi Ma,Isabella Renzi,Wing Pui Kong,Stephen D. Schmidt,Lingshu Wang,Yi Zhang,Emily Phung,Emily Phung,Lauren A. Chang,Rebecca J. Loomis,Nedim Emil Altaras,Elisabeth Narayanan,Mihir Metkar,Vlad Presnyak,Cuiping Liu,Mark K. Louder,Wei Shi,Kwanyee Leung,Eun Sung Yang,Ande West,Kendra Gully,Laura J. Stevens,Nianshuang Wang,Daniel Wrapp,Nicole A. Doria-Rose,Guillaume Stewart-Jones,Hamilton Bennett,Gabriela S. Alvarado,Martha Nason,Tracy J. Ruckwardt,Jason S. McLellan,Mark R. Denison,James D. Chappell,Ian N. Moore,Kaitlyn M. Morabito,John R. Mascola,Ralph S. Baric,Andrea Carfi,Barney S. Graham +62 more
TL;DR: In this article, an mRNA vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is proposed, which is used to control the CoVID-19 global pandemic.
Posted ContentDOI
mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants
Kai Wu,Anne P. Werner,Juan I. Moliva,Matthew A. Koch,Angela Choi,Guillaume Stewart-Jones,Hamilton Bennett,Seyhan Boyoglu-Barnum,Wei Shi,Barney S. Graham,Andrea Carfi,Kizzmekia S. Corbett,Robert A. Seder,Darin K. Edwards +13 more
TL;DR: In this paper, the authors assessed the neutralizing capacity of sera from human subjects or non-human primates (NHPs) that received mRNA-1273 vaccination, using two orthogonal VSV and lentivirus PsVN assays expressing spike variants of 20E (EU1), 20A.7, and B.1.351.
Journal ArticleDOI
Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.
Kai Wu,Anne P. Werner,Matthew A. Koch,Angela Choi,Elisabeth Narayanan,Guillaume Stewart-Jones,Tonya M. Colpitts,Hamilton Bennett,Seyhan Boyoglu-Barnum,Wei Shi,Juan I. Moliva,Nancy J. Sullivan,Barney S. Graham,Andrea Carfi,Kizzmekia S. Corbett,Robert A. Seder,Darin K. Edwards +16 more
TL;DR: In this paper, the mRNA-1273 vaccine was shown to neutralize the P.1.1 lineage, the B. 1.7 lineage, and B. 7 lineage plus t
Journal ArticleDOI
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis.
Angela Choi,Matthew A. Koch,Kai Wu,Laurence Chu,LingZhi Ma,Anna Hill,Naveen Nunna,Wenmei Huang,Judy Oestreicher,Tonya M. Colpitts,Hamilton Bennett,Holly Legault,Yamuna Paila,Biliana Nestorova,Baoyu Ding,David C. Montefiori,Rolando Pajon,Jacqueline M. Miller,Brett Leav,Andrea Carfi,Roderick McPhee,Darin K. Edwards +21 more
TL;DR: In this paper, the authors evaluated the safety and immunogenicity of a single booster dose of mRNA-1273 or variant-modified mRNAs, including multivalent mRNA 1273.
Journal ArticleDOI
Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates.
Kizzmekia S. Corbett,Martha Nason,Britta Flach,Matthew Gagne,Sarah O’Connell,Timothy S. Johnston,Shruti N. Shah,Venkata Viswanadh Edara,Katharine Floyd,Lilin Lai,Charlene McDanal,Joseph R. Francica,Barbara J. Flynn,Kai Wu,Angela Choi,Matthew A. Koch,Olubukola M. Abiona,Anne P. Werner,Juan I. Moliva,Shayne F. Andrew,Mitzi M. Donaldson,Jonathan Fintzi,Dillon R. Flebbe,Evan Lamb,Amy T. Noe,Saule T. Nurmukhambetova,Samantha J. Provost,Anthony L. Cook,Alan Dodson,Andrew Faudree,Jack Greenhouse,Swagata Kar,Laurent Pessaint,Maciel Porto,Katelyn Steingrebe,Daniel Valentin,Serge Zouantcha,Kevin W. Bock,Mahnaz Minai,Bianca M. Nagata,Renee van de Wetering,Seyhan Boyoglu-Barnum,Kwanyee Leung,Wei Shi,Eun Sung Yang,Yi Zhang,John Paul Todd,Lingshu Wang,Gabriela S. Alvarado,Hanne Leth Andersen,Kathryn E. Foulds,Darin K. Edwards,John R. Mascola,Ian N. Moore,Mark G. Lewis,Andrea Carfi,David C. Montefiori,Mehul S. Suthar,Adrian B. McDermott,Mario Roederer,Nancy J. Sullivan,Daniel C. Douek,Barney S. Graham,Robert A. Seder +63 more
TL;DR: In this paper, nonhuman primates (NHPs) received either no vaccine or doses ranging from 0.3 to 100 μg of the mRNA-12 protein, which can be used as surrogate endpoints for vaccine efficacy.